Simple Summary The poor prognosis outcome of patients with KRAS mutations (KRAS mut)
was correlated with an immunosuppressive tumor microenvironment (TME). At the gene …

Background KRAS gene is the most common type of mutation reported in colorectal cancer
(CRC). KRAS mutation-mediated regulation of immunophenotype and immune pathways in …

Purpose: KRAS mutation is a common canonical mutation in colorectal cancer, found at
differing frequencies in all consensus molecular subtypes (CMS). The independent …

KRAS mutation is the most frequent oncogenic aberration in colorectal cancer (CRC). The
molecular mechanism and clinical implications of KRAS mutation in CRC remain unclear …

Oncogenic KRAS mutations are well-described functionally and are known to drive
tumorigenesis. Recent reports describe a significant prevalence of KRAS allelic imbalances …

Background The main objective of this study was to analyze the effects of KRAS/TP53
mutation status and tumor sideness on the immune microenvironment of colorectal cancer …

Mutations of the KRAS oncogene are predictive for resistance to treatment with antibodies
against the epithelial growth factor receptor in patients with colorectal cancer. Overcoming …

The heterogeneity of colon cancer tumors suggests that therapeutics targeting specific
molecules may be effective in only a few patients. It is therefore necessary to explore gene …

Purpose KRAS mutation is an important predictive marker in determining resistance to anti-
Epidermal Growth Factor Receptor (EGFR) antibody therapies. In order to clarify whether not …

KRAS mutation is responsible for 40–50% of colorectal cancers (CRCs). RNA-seq data and
bioinformatics methods were used to analyze the transcriptional profiles of KRAS mutant …